Serum inflammatory markers and colorectal cancer risk and survival

Sundeep Ghuman¹, Mieke Van Hemelrijck¹, Hans Garmo¹,², Lars Holmberg¹,²,³, Håkan Malmström⁴, Mats Lambe²,⁵, Niklas Hammar⁶,⁷, Göran Walldius⁷, Ingmar Jungner⁸ and Wahyu Wulaningsih *,¹,⁹

¹Cancer Epidemiology Group, Division of Cancer Studies, King’s College London, London, UK; ²Regional Cancer Centre, Uppsala, Sweden; ³Department of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden; ⁴Department of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; ⁵Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; ⁶AstraZeneca R&D, Möln达尔, Sweden; ⁷Department of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; ⁸Department of Medicine, Clinical Epidemiological Unit, Karolinska Institutet and CALAB Research, Stockholm, Sweden and ⁹Medical Research Council Unit for Lifelong Health and Ageing at University College London, London, UK

Background: Inflammation has been linked with development of some cancers. We investigated systemic inflammation in relation to colorectal cancer incidence and subsequent survival using common serum inflammatory markers.

Design: A cohort of men and women aged 20 years and older in greater Stockholm area with serum C-reactive protein (CRP) and albumin measured between 1986 and 1999 were included (n = 325599). A subset of these had baseline measurements of haptoglobin and leukocytes. Multivariable Cox regression was performed to assess risk of colorectal cancer by levels of inflammatory markers, adjusting for potential confounders. Analyses were stratified by circulating glucose, total cholesterol and triglycerides. Overall and CRC-specific death following diagnosis were assessed as secondary outcomes.

Results: A total of 4764 individuals were diagnosed with colorectal cancer. A positive association between haptoglobin and colorectal cancer incidence was found (hazard ratio (HR): 1.17; 95% CI: 1.06–1.28). A positive association was also observed with leukocytes (HR: 1.21; 95% CI: 1.03–1.42). No evidence of association was noted between CRP and colorectal cancer risk. Higher risks of all-cause death were seen with haptoglobin and leukocytes levels. Higher haptoglobin levels were linked with an increased risk of colorectal cancer death (HR: 1.19; 95% CI: 1.01–1.41).

Conclusions: Prediagnostic systemic inflammation may impact colorectal cancer incidence and survival; therefore, prompting investigations linking inflammatory pathways preceding colorectal cancer with disease severity and progression.

Evidence suggesting a role for inflammation in colorectal carcinogenesis is growing (Hanahan and Weinberg, 2011). For instance, inflammatory bowel disease, reflecting local inflammation of the colon, has been associated with an increased risk of colorectal cancer (Jess et al, 2012). The role of systemic inflammation in colon carcinogenesis, however, remains unclear. Chronic inflammation may initiate and promote cancer through the generation of proinflammatory cytokines and reactive oxygen species, such as interleukin-6 (IL-6), which activates transcription factors that can promote the growth of a tumour (Meira et al, 2008). Increases in white blood cells can also lead to a ‘respiratory burst’ due to an increased uptake of oxygen, resulting in more reactive oxygen species at the site of damage and DNA damage consequently (Reuter et al, 2010).

In the context of colorectal cancer, over 19 observational studies have investigated a link with prediagnostic levels of inflammatory markers over the past decade (Supplementary Table S1). Most of these studies have used C-reactive protein (CRP). Findings varied,
with nine studies having reported a positive association between CRP and colorectal cancer risk. A meta-analysis in 2013 found no statistical significance (hazard ratio (HR) 1.055; 95% CI: 0.925–1.184), but concluded there could be a possible link between elevated CRP levels and colorectal cancer (Guo et al, 2013). Therefore, the link between markers of chronic inflammation and risk of colorectal cancer is still unclear.

We investigated the link between inflammation and colorectal cancer risk in a cohort of the Apolipoprotein Mortality Risk Study (AMORIS) Study (n = 325 599). In addition to commonly studied CRP, we also assessed albumin, haptoglobin and white blood cells as markers of inflammation in relation to risk of colorectal cancer. C-reactive protein, an acute phase reactant, is elevated in response to inflammation following a rise in proinflammatory interleukin-6 (IL-6) and is the most widely used marker to assess inflammation in clinic (Skinner et al, 2010). Similar to CRP, haptoglobin levels also rise in the presence of increased IL-6 levels (Rodriguez-Hernandez et al, 2013). On the other hand, albumin levels drop in response to inflammation; hence, albumin is regarded as a negative acute phase reactant (Fox et al, 2013). Second, we studied prediagnostic levels of these inflammatory markers in relation to survival among colorectal cancer patients (n = 4764). We also considered metabolic disorders by assessing serum markers of glucose and lipid metabolism.

### Study population

The AMORIS Study has been described in further detail elsewhere (Holme et al, 2010). Briefly, this cohort consists of men and women from the greater Stockholm area in Sweden who underwent clinical laboratory testing at the Central Automation Laboratory (CALAB) in Stockholm, Sweden, with follow-up information collected from Swedish national registries. In CALAB, over 500 blood biomarkers were collected between 1986 and 1996. All the individuals at the time were either healthy individuals referred for clinical laboratory testing as part of a general health check-up or were outpatients. None of the individuals were in-patients at the time their blood samples were taken. Apart from the information on blood testing, no clinical data was included in the CALAB database. With a ten-digit personal identification number, the CALAB database was linked to several Swedish national registries such as the National Cancer Register, the Hospital Discharge Register, the Cause of Death Register, the consecutive Swedish Censuses during 1970–1990 and the National Register of Emigration. These databases provided data on socioeconomic status, vital status, cancer diagnosis, comorbidity and emigration. All aspects of the AMORIS Study complied with the Declaration of Helsinki and the ethics review board of Karolinska Institute approved the AMORIS Study.

For this study, all individuals aged 20 years and older with baseline measurements of CRP and albumin (n = 325 599) were included, among which 218 158 also had baseline haptoglobin levels measured, 96 821 had leukocytes measurements and 57 340 participants had body mass index (BMI) measurements. None of the participants had a history of cancer at baseline. Participants with measurements of serum inflammatory markers taken within 2 years before the end of follow-up were excluded to reduce the possibility of reverse causation.

### Outcome assessment

The main outcome of interest was diagnosis of colorectal cancer as obtained from the Swedish Cancer Register using the International Code of Diseases, version 7 (ICD-7 code: 153-154). As a secondary outcome, we investigated mortality from colorectal cancer and from all causes for which we obtained information from the Cause of Death Register. The follow-up time for the primary outcome was defined as the time from baseline measurement entry until time of colorectal cancer diagnosis, death, emigration out of Sweden or the closing date of the study (31 December 2011), whichever came first. Those who were diagnosed with CRC in this study were then followed to assess death from all causes and from CRC as the second outcome. For the mortality outcomes, follow-up time was defined from the diagnosis of colorectal cancer to either death, end of follow-up or date of emigration out of Sweden, whichever came first.

### Serum inflammatory markers

Serum CRP and haptoglobin levels were measured with an immunoturbidimetric assay (reagents from Orion Diagnostics, Espoo, Finland). These were analysed using fully automated multichannel analysers. For CRP, an Auto Chemist-PRISMA was used from 1985 to 1992 and from 1993 to 1996 a DAX96 from Technicon Instruments (Bayer Diagnostics, New York, NY, USA) was used. Hitachi-analysers (Mannheim, Germany) were used to analyse haptoglobin (Holme et al, 2010). At the time of laboratory examination (1985–1996), high-sensitivity CRP (hs-CRP) was not available and CRP concentrations below the level of 10 mg l⁻¹ could not be discriminated. However, the cutoff point of 10 mg l⁻¹ is widely accepted as the upper limit of the health-associated reference range (Wilkins et al, 1998). Albumin was measured with a bromcresol green method. Leukocyte count was measured with routinely used haematology analysers from STKS Haematology System (Beckman Coulter Inc., Fullerton, CA, USA). Total imprecision calculated by the coefficient of variation was 12% for CRP, 5.6% for haptoglobin, <1.8% for albumin and for <2.7% for leukocytes (Wulaningsih et al, 2015). Central Automation Laboratory performed all laboratory procedure and complied with the WHO international federation of clinical chemistry protocols standard programmes (Jungner et al, 1998).

### Covariates

In addition to the inflammatory markers of interest, information on serum levels of glucose, triglycerides (TGs) and total cholesterol (TC) levels were collected due to research indicating metabolic syndrome, specifically its components as potential confounders (Esposito et al, 2013). Glucose was measured with a glucose oxidase/peroxidase method (Holme et al, 2010). Total cholesterol and TGs were measured enzymatically with standardised procedures. Body mass index was calculated from weight (kg) and height (m) measured at CALAB. Information on education and social economic status (SES) was obtained from the national censuses. History of ulcerative colitis (UC) was obtained from the National Patient Register. Also from the National Patient Register, comorbidities were assessed as the Charlson comorbidity index (CCI), which consists of 17 groups of diseases with a specific weight assigned to each disease category (D’Hoore et al, 1996). These weights were then summed to obtain an overall score, resulting in four comorbidity levels (0, 1, 2 and 3 + ), indicating no comorbidity to severe comorbidity. Period of diagnosis was categorised (before and after 2008) to account for colorectal cancer screening introduced in Sweden from 2008 (Blom et al, 2014). Interval time was defined as time between blood test and the time of diagnosis of colorectal cancer. Information on tumour stage was available for 2474 out of 4764 colorectal cancer cases from the Swedish Cancer Registry.

### Statistical analysis

First, risk of colorectal cancer associated with continuous log-transformed values of systemic inflammatory markers (C-reactive protein, albumin, haptoglobin and leukocytes) were analysed using unadjusted Cox proportional hazard regression models. For CRP, all logarithmic analysis was carried out with participants who had CRP values > 10 mg l⁻¹. Proportionality of the hazard was checked with Kaplan–Meier curves and the assumption of proportionality was not violated. Additionally, inflammatory markers were assessed as categories, with CRP divided into five categories (<10, 10–15, 15–25, 25–50 and
RESULTS

During a mean follow-up time of 18 years, 4764 out of 325 599 participants (1.46%) developed invasive colorectal cancer. Table 1 shows participant characteristics by colorectal cancer diagnosis. Over 90% of participants were gainfully employed.

Higher levels of haptoglobin and leukocytes levels were associated with increased colorectal cancer risk in the crude model (Table 2). In the second model adjusted for age, sex, education, SES, CCI and UC, these trends weakened slightly, with HRs of 1.19 (95% CI: 1.09–1.31) and 1.25 (95% CI: 1.07–1.46) for highest vs lowest quartile in haptoglobin and leukocytes, respectively. When additionally adjusted for CRP and BMI in this subgroup, no marked changes were observed (Table 5). In the fully adjusted models, significant trends for albumin, haptoglobin and leukocytes were observed (Table 5). In the fully adjusted models, significant trends for albumin, haptoglobin and leukocytes were observed (Table 5).

DISCUSSION

This is the largest study to date assessing the association between colorectal cancer risk and widely available clinical markers of inflammation in addition to CRP. To our knowledge, this is the first study to assess the relationship between haptoglobin, albumin and leukocytes in relation to CRC incidence and survival. Despite the lack of an association with CRP, we found an increased risk of...
Inflammatory markers and colorectal cancer

Biological studies linking inflammation to colorectal cancer and cancer development in general have suggested a role of cancer initiation and promotion by reactive oxygen species, which is produced during inflammation (Wiseman and Halliwell, 1996; Gabay and Kushner, 1999). This variation in bioavailability of the markers may explain the difference in results observed between the two markers. Furthermore, this may indicate that haptoglobin, in addition to its role as an inflammatory marker, could be directly involved in CRC carcinogenesis. Further studies are necessary to contrast the role of haptoglobin with other markers such as CRP as markers of chronic inflammation in the context of cancer. Higher quartiles of leukocytes showed a positive association with risk of colorectal cancer. This positive association agrees with findings indicating the difference of IL-6, which is released by specific leukocytes, in CRC carcinogenesis (Ye et al, 2003; Álvarez-Blasco et al, 2009). Serum haptoglobin levels rise for longer periods following an external insult compared with other inflammatory markers such as CRP, which fluctuates and drops rapidly after a proinflammatory stimulus (Gabay and Kushner, 1999). This variation in bioavailability of the markers may explain the difference in results observed between the two markers. Furthermore, this may indicate that haptoglobin, in addition to its role as an inflammatory marker, could be directly involved in CRC carcinogenesis. Further studies are necessary to contrast the role of haptoglobin with other markers such as CRP as markers of chronic inflammation in the context of cancer. Higher quartiles of leukocytes showed a positive association with risk of colorectal cancer. This positive association agrees with findings indicating the role of IL-6, which is released by specific leukocytes, in CRC carcinogenesis (Patel et al, 2014).

In keeping with the majority of current studies, our finding found no evidence of association between elevated CRP and CRC. As already mentioned, of the 19 prospective studies that have been published to date, only nine found that CRP is associated with an increased risk of colorectal cancer (Supplementary Table S1). However, the largest number of colorectal cancer cases among these prior studies was 729 (Lee et al, 2011). In addition to sample size, adjustments for potential confounders such as BMI and other lifestyle factors may explain the differences in estimates. Although our analysis in the subgroup with BMI information was hampered by low statistical power, we observed similar results before and after adjustment for BMI or markers of glucose and lipid metabolisms.

### Inflammatory markers and colorectal cancer

**Table 2. Associations between inflammatory markers and risk of CRC**

| Marker         | n CRC/n total | Hazard ratio (95% CI) | Hazard ratio (95% CI) | Hazard ratio (95%) |
|---------------|---------------|-----------------------|-----------------------|-------------------|
| **CRP (mg l<sup>-1</sup>)** |               |                       |                       |                   |
| Continuous log<sup>a</sup> | 295/17 852 | 0.91 (0.77–1.07) | 0.85 (0.72–1.01) | 0.87 (0.73–1.04) |
| <10           | 3930/27 9599 | 1 (reference) | 1 (reference) | 1 (reference) |
| 10–15         | 635/33 556 | 1.12 (1.03–1.22) | 1.02 (0.94–1.11) | 1.03 (0.90–1.34) |
| 15–25         | 104/6053 | 1.26 (1.04–1.53) | 1.11 (0.92–1.35) | 1.10 (0.90–1.34) |
| 25–50         | 57/3953 | 1.05 (0.81–1.36) | 0.88 (0.68–1.14) | 0.93 (0.72–1.21) |
| > 50          | 38/2438 | 1.14 (0.83–1.57) | 0.89 (0.65–2.3) | 0.88 (0.63–1.23) |
| **Haptoglobin (g l<sup>-1</sup>)** |               |                       |                       |                   |
| Continuous log<sup>b</sup> | 3645/218 158 | 2.01 (1.86–2.36) | 1.28 (1.14–1.44) | 1.24 (1.10–1.40) |
| <0.90         | 704/53 597 | 1 (reference) | 1 (reference) | 1 (reference) |
| 0.90–1.00     | 470/30 725 | 1.19 (1.06–1.34) | 1.083 (0.96–1.22) | 1.09 (0.97–1.22) |
| 1.00–1.20     | 1090/66 060 | 1.31 (1.19–1.44) | 1.07 (0.97–1.18) | 1.06 (0.96–1.17) |
| > 1.20        | 1381/67 776 | 1.70 (1.56–1.86) | 1.19 (1.09–1.31) | 1.17 (1.06–1.28) |
| **Leukocytes (10<sup>9</sup>/l)** |               |                       |                       |                   |
| Continuous log| 1392/96 821 | 1.322 (1.10–1.56) | 1.37 (1.18–1.65) | 1.30 (1.07–1.58) |
| <5.20         | 284/22 695 | 1 (reference) | 1 (reference) | 1 (reference) |
| 5.2–3         | 355/25 147 | 1.15 (0.98–1.34) | 1.10 (0.94–1.28) | 1.08 (0.92–1.27) |
| 6.3–7.6       | 386/24 223 | 1.32 (1.13–1.54) | 1.24 (1.06–1.45) | 1.22 (1.04–1.43) |
| > 7.6         | 367/24 956 | 1.23 (1.07–1.45) | 1.25 (1.07–1.46) | 1.21 (1.03–1.42) |

Abbreviations: CRC = colorectal cancer; CRP = C-reactive protein; UC = ulcerative colitis.

<sup>a</sup>Crude model.

<sup>b</sup>Adjusted for age, sex, education and socioeconomic status, Charlson comorbidity index and UC.

<sup>c</sup>Adjusted for age, sex, education and socioeconomic status, Charlson comorbidity index and UC, glucose, total cholesterol and triglycerides.
### Table 3. Characteristics of survival study participants

|                       | All-cause death (n = 2257) | CRC death (n = 1467) | Alive (n = 2507) | All CRC patients (n = 4764) |
|-----------------------|-----------------------------|----------------------|------------------|-----------------------------|
| **Age at diagnosis**  |                             |                      |                  |                             |
|                       | 71.16 (10.72)               | 69.32 (10.78)        | 67.04 (10.06)    | 68.99 (10.58)               |
| **Sex**               |                             |                      |                  |                             |
| Male                  | 1329 (48.47)                | 838 (30.56)          | 1413 (51.53)     | 2742 (57.66)                |
| Female                | 928 (45.90)                 | 629 (13.20)          | 1094 (54.10)     | 2022 (42.44)                |
| **Interval between marker measurements and diagnosis (years)** | 10.91 (5.17) | 11.21 (5.23) | 14.46 (5.62) | 12.78 (5.50) |
| **Follow-up since diagnosis (years)** | 2.98 (3.35) | 2.00 (2.12) | 6.13 (4.87) | 4.64 (4.50) |
| **Period diagnosis**  |                             |                      |                  |                             |
| < 2008                |                             |                      |                  |                             |
| > 2008                |                             |                      |                  |                             |
| **TNM staging**       |                             |                      |                  |                             |
| Tumour                |                             |                      |                  |                             |
| ≤ T2                  |                             |                      |                  |                             |
| > T2                  |                             |                      |                  |                             |
| Tx/unknown            |                             |                      |                  |                             |
| Nodes                 |                             |                      |                  |                             |
| No                    |                             |                      |                  |                             |
| Yes                   |                             |                      |                  |                             |
| Nx/Missing            |                             |                      |                  |                             |
| Metastasis            |                             |                      |                  |                             |
| No                    |                             |                      |                  |                             |
| Yes                   |                             |                      |                  |                             |
| Mx/Unknown            |                             |                      |                  |                             |
| **Markers**           |                             |                      |                  |                             |
| CRP (mg l⁻¹)          |                             |                      |                  |                             |
| Mean (s.d.)           | 18.92 (39.60)               | 18.35 (31.35)        | 19.43 (38.35)    | 18.92 (39.60)               |
| Albumin (g l⁻¹)       |                             |                      |                  |                             |
| Mean (s.d.)           | 42.14 (2.72)                | 42.27 (2.71)         | 42.78 (2.63)     | 42.48 (2.96)                |
| Haptoglobin (g l⁻¹)   |                             |                      |                  |                             |
| Mean (s.d.)           | 1.13 (0.33)                 | 1.12 (0.32)          | 1.07 (0.39)      | 1.10 (0.31)                 |
| Leukocytes (10⁹/l)    |                             |                      |                  |                             |
| Mean (s.d.)           | 6.76 (1.97)                 | 6.74 (2.06)          | 6.59 (1.93)      | 6.68 (1.95)                 |

Abbreviations: CRC = colorectal cancer; CRP = C-reactive protein; TNM = tumour node metastasis.

### Table 4. Associations between prediagnostic inflammatory markers and all-cause death

| Marker     | N event/N total | Hazard ratios (95% CI)ᵃ | Hazard ratios (95% CI)ᵇ | Hazard ratios (95% CI)ᶜ |
|------------|-----------------|-------------------------|-------------------------|-------------------------|
| **CRP (mg l⁻¹)** |                 |                         |                         |                         |
| Continuous log |                 |                         |                         |                         |
| < 10       | 149/295         | 0.96 (0.79–1.18)        | 0.93 (0.75–1.15)        | 0.92 (0.74–1.14)        |
| 10–15      | 1834/3930       | 1.06 (0.94–1.19)        | 1.04 (0.92–1.17)        | 1.02 (0.91–1.15)        |
| 15–25      | 51/104          | 1.01 (0.77–1.34)        | 0.86 (0.65–1.14)        | 0.92 (0.70–1.22)        |
| 25–50      | 29/57           | 1.17 (0.81–1.69)        | 1.17 (0.81–1.69)        | 1.28 (0.89–1.85)        |
| > 50       | 21/38           | 1.11 (0.72–1.70)        | 1.03 (0.67–1.58)        | 1.07 (0.70–1.65)        |

**P**trend: 0.26 0.8 0.5

| **Albumin** |                 |                         |                         |                         |
| Continuous log |                 |                         |                         |                         |
| < 41       | 2256/4764       | 0.13 (0.07–0.24)        | 0.63 (0.32–1.25)        | 0.57 (0.29–1.14)        |
| 41–43      | 615/1065        | 1.06 (0.94–1.19)        | 1.04 (0.92–1.17)        | 1.02 (0.91–1.15)        |
| 43–45      | 601/1290        | 0.76 (0.68–0.85)        | 0.82 (0.74–0.92)        | 0.88 (0.78–0.98)        |
| > 45       | 415/1044        | 0.68 (0.60–0.77)        | 0.90 (0.79–1.02)        | 0.88 (0.77–1.00)        |

**P**trend: 0.001 0.5 0.28

| **Haptoglobin** |                 |                         |                         |                         |
| Continuous log |                 |                         |                         |                         |
| < 0.90       | 1793/3645       | 1.38 (1.16–1.63)        | 1.27 (1.07–1.50)        | 1.28 (1.08–1.51)        |
| 0.90–1.00    | 324/704         | 1.04 (0.90–1.19)        | 1.02 (0.89–1.17)        | 1.04 (0.91–1.20)        |
| > 1.20       | 755/1381        | 1.12 (1.07–1.39)        | 1.16 (1.02–1.32)        | 1.19 (1.05–1.36)        |

**P**trend: <0.0001 0.002 0.001

| **Leukocytes (10⁹/l)** |                 |                         |                         |                         |
| Continuous log |                 |                         |                         |                         |
| < 5.20       | 741/1392        | 1.42 (1.10–1.85)        | 1.64 (1.25–2.15)        | 1.63 (1.26–2.12)        |
| 5.2–6.3      | 136/284         | 1.04 (0.90–1.19)        | 1.02 (0.89–1.17)        | 1.04 (0.91–1.20)        |
| 6.3–7.6      | 194/355         | 1.30 (1.04–1.62)        | 1.30 (1.04–1.62)        | 1.35 (1.08–1.69)        |
| > 7.6        | 201/368         | 1.20 (0.95–1.53)        | 1.19 (0.95–1.48)        | 1.29 (1.04–1.61)        |

**P**trend: <0.0001 0.001

Abbreviations: CI = confidence interval; CRP = C-reactive protein; TNM = tumour node metastasis.

ᵃCrude model.

ᵇAdjusted for age of diagnosis, interval time, period of diagnosis and sex.

ᶜAdjusted for age of diagnosis, interval time, period of diagnosis and sex and TNM staging.

dCRP > 10 mg l⁻¹.
For the mortality outcomes, haptoglobin was the only one that showed a positive association with colorectal cancer death. Our findings suggest better overall survival with low or normal levels of haptoglobin and leukocytes before diagnosis, indicating a role of prediagnostic inflammation in survival after diagnosis. There is currently limited data on prediagnostic serum inflammatory markers and CRC survival. In a study by Allin et al (2009), levels of prediagnostic CRP levels and the risk of death from cancer was studied. They found elevated baseline CRP to be associated with early death after a diagnosis of any cancer, particularly in patients without metastases. However, the study by Allin et al (2009) only had 191 patients with colorectal cancer, which may explain the differences in the present study. Associations observed in our study were stronger for all-cause death than colorectal cancer death. This may indicate a competing risk situation, in which dying from other causes, such as cardiovascular disease, may remove patients from being at risk of dying from colorectal cancer (Satagopan et al, 2004). Therefore, analysis of cancer-specific death is necessary in studying the potential role of elevated prediagnostic inflammation in cancer survival.

**Strengths and limitations.** The major strength of this study is the large number of participants and cases of colorectal cancer. To date, this is by far the largest population-based study assessing common inflammatory markers and colorectal cancer. The largest study to date had 1096 cases of colorectal cancer (Aleksandrova et al, 2010). This study was also the first to assess the relationship between haptoglobin, albumin and leukocytes in relation to CRC incidence and survival. All biomarker analyses for this study were performed at the same laboratory in Stockholm. Moreover, data for all participants in this study was taken from national registers, providing complete follow-up for all study participants and detailed information on participant’s comorbidities, cancer diagnosis, deaths and social statuses. The population in the study was selected by the analysis of fresh blood samples from non-hospitalised individuals. However, any healthy cohort effect would not have an effect on the internal validity of the study (Van Hemelrijck et al, 2011).

One of the main limitations of this study is that hs-CRP was not available at the time the blood samples were analysed. Therefore, it was not possible to quantify any CRP value below 10 mg l$^{-1}$. This may have resulted in the underestimation of the association between serum CRP and colorectal cancer. However, to the best of our knowledge, there has been no study to address the difference between using non-hs-CRP and hs-CRP in the context of cancer risk. We have also used the cutoff that has been suggested has medically relevant when using non hs-CRP (Wilkins et al, 1998). The majority of participants had undetectable CRP levels, which hampered our analysis using continuous CRP. Therefore, similar to the previous study, we assessed CRP in categories (Van Hemelrijck et al, 2011). Participants with measurements of serum inflammatory markers taken within 2 years before colorectal cancer diagnosis were excluded to reduce the possibility of reverse causation. However, colorectal cancer usually develops years before diagnosis. During the earlier years, before screening was common, this long latency period may have had a greater impact. Therefore, our analysis was adjusted for period of diagnosis to account for the differences in early detection and management of colorectal cancer.
over time. Since cancer may influence levels of serum inflammatory markers, residual confounding may still have occurred despite exclusion of participants with history of any cancer at baseline. Owing to the rounding of the marker levels to 2 decimal places, the distribution of the markers was not completely equal between the quartiles. In this study, we were not able to adjust for exercise, alcohol intake, fruit and vegetable and/or fibre intake, aspirin and other NSAID use owing to the lack of information in this study. We did not have information on Crohn’s disease; however, the history of UC was included in our analysis to account for inflammatory bowel disease. The AMORIS population is representative of the general working population of Stockholm (Walldius et al, 2001). However, this healthy cohort effect does not influence the internal validity of the study. The markers assessed in this study were measured at one single point in time, which may be prone to a non-differential measurement error and this may have resulted in the underestimation of the associations observed in this study. Finally, detailed histopathological information of the tumour was not available and it may benefit future studies to further explore whether prediagnostic inflammation corresponds to any specific or molecular subtypes of colorectal cancer.

**CONCLUSION**

We found that altered levels of prediagnostic inflammatory markers may be associated with an increased risk of colorectal cancer and worse cancer-specific survival after diagnosis. These findings support the importance of systemic inflammation preceding cancer diagnosis in affecting subsequent risk of incidence and survival. Therefore, this denotes the importance to study the roots of systemic inflammation and pathways specific to the development and progression of colorectal cancer.

**ACKNOWLEDGEMENTS**

The research was funded/supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at the Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. The views expressed are those of the author(s) and not necessarily those of the CRUK, NHS, the NIHR or the Department of Health.

**CONFLICT OF INTEREST**

NH is employed by AstraZeneca. However, the views expressed in this study are his own and not those of AstraZeneca’s. The other authors declare no conflict of interest.

**REFERENCES**

NCEP (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285(19): 2486–2497.

Aleksandrova K, Jenab M, Boeing H, Jansen E, Bueno-de-Mesquita HB, Rinaldi S, Riboli E, Overvad K, Dahm CC, Olsen A, Tjonneland A, Boutron-Ruault MC, Clavel-Chapelon F, Morois S, Palli D, Krogh V, Tumino R, Vineis P, Panico S, Kaaks R, Rohrmann S, Trichopoulou A, Lagiou P, Trichopoulou D, van Duijnhoven FJ, Leufkens AM, Peeters PH, Rodriguez L, Bonet C, Sanchez MJ, Donorrosno M, Navarro C, Barricarte A, Palmqvist R, Hellman S, Khaw KT, Wareham N, Allen NE, Spencer E, Romaguera D, Norat T, Peschon T (2010) Circulating C-reactive protein concentrations and risks of colon and rectal cancer: a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. *Am J Epidemiol* 172(4): 407–418.

Allin KH, Bojesen SE, Nordestgaard BG (2009) Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. *J Clin Oncol* 27(13): 2217–2224.

Álvarez-Blasco F, Martínez-García M, Luque-Ramírez M, Parraza N, San Millán JL, Escobar-Morreale HF (2009) Role of haptoglobin in polycystic ovary syndrome (PCOS), obesity and disorders of glucose tolerance in premenopausal women. *PLoS One* 4: e5606.

Blom J, Kilpeläinen S, Hultcrantz R, Tornberg S (2014) Five-year experience of organized colorectal cancer screening in a Swedish population—increased compliance with age, female gender, and subsequent screening round. *J Med Screen* 21(3): 144–150.

Bollrath J, Phesse TJ, von Burstin VA, Putozcki T, Bennecke M, Bateman T, Nebelieck T, Lundgren-May T, Canli O, Schwiattalla S, Matthews V, Schmid RM, Kirchner T, Arkan MC, Ernst M, Greten FR (2009) Gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. *Cancer Cell* 15(2): 91–102.

D’Hoore W, Bouchaert A, Tilquin C (1996) Practical considerations on the use of the Charlson comorbidity index with administrative data bases. *J Clin Epidemiol* 49(12): 1429–1433.

Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MJ, Rafaniello C, Panagiotakos DB, Giugliano D (2013) Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. *Endocrine* 44(3): 634–647.

Fox P, Hudson M, Brown C, Lord S, Gebski V, De Souza P, Lee CK (2013) Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. *Br J Cancer* 109(1): 147–153.

Gaby C (2006) Interleukin-6 and chronic inflammation. *Arthritis Res Ther* 8(Suppl 2): S3.

Gaby C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. *N Engl J Med* 340(6): 448–454.

Guo YZ, Pan L, Du CJ, Ren DQ, Xie XM (2013) Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies. *Asian Pac J Cancer Prev* 14(1): 243–248.

Hahn S, Jackstadt R, Siemens H, Huntten S, Hermeking H (2013) SNAI1 and miR-34a feed-forward regulation of ZNF281/ZBP99 promotes epithelial–mesenchymal transition. *Embo J* 32(23): 3079–3095.

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. *Cell* 144(5): 646–674.

Hodge DR, Hurt EM, Farrar WL (2005) The role of IL-6 and STAT3 in inflammation and cancer. *Eur J Cancer* 41(16): 2502–2512.

Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G (2010) Inflammatory markers, lipoprotein components and risk of major cardiovascular events in 65 005 men and women in the Apolipoprotein MOrtality RisK study (AMORIS). *Atherosclerosis* 213(1): 299–305.

Jungner I, Marcovina SM, Walldius G, Holme I, Julkner W, Steiner E (1998) Apolipoprotein B and A-I values in 147576 Swedish males and females, standardized according to the World Health Organization-International Federation of Clinical Chemistry First International Reference Materials. *Clin Chem* 44(8 Part 1): 1641–1649.

Lee S, Choe JW, Kim HK, Sung J (2011) High-sensitivity C-reactive protein and cancer. *J Epidemiol* 21(3): 161–168.

Meira LB, Bugnij JM, Green SL, Lee CW, Pang B, Borenshtein D, Rickman BH, Rogers AR, Moroski-Erkul CA, McFauline JL, Schauer DR, Deduc P, Fox JG, Samson LD (2008) DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. *J Clin Invest* 118: 2516–2525.

Patel SA, Bhamra U, Charalambous MP, David RM, Edwards RJ, Lightfoot T, Boobis AR, Gooderham NJ (2014) Interleukin-6 mediated upregulation of CYP1B1 and CYP2E1 in colorectal cancer involves DNA methylation, inflammation, and cancer: How are they linked? *Br J Cancer* 111(12): 2287–2296.

Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB (2010) Oxidative stress, inflammation, and cancer: How are they linked? *Free Radic Biol Med* 49(11): 1603–1616.

Rodriguez-Hernandez H, Simental-Mendia LE, Rodriguez-Ramirez G, Reyes-Romero MA (2013) Obesity and inflammation: epidemiology, risk factors, and markers of inflammation. *Int J Endocrinol* 2013: 678159.

Rokavec M, Oner MG, Li H, Jackstadt R, Jiang L, Lodigian D, Keller M, Horst D, Ziegler PK, Schwiattalla S, Slotta-Huspenina J, Bader FG, Greten FR, Hermeking H (2014) IL-6R/STAT3/miR-34a feedback loop promotes
EMT-mediated colorectal cancer invasion and metastasis. *J Clin Invest* 124(4): 1853–1867.

Rose-John S (2012) IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. *Int J Biol Sci* 8(9): 1237–1247.

Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD (2004) A note on competing risks in survival data analysis. *Br J Cancer* 91(7): 1229–1235.

Siemens H, Neumann J, Jackstadt R, Mansmann U, Horst D, Kirchner T, Hermeking H (2013) Detection of miR-34a promoter methylation in combination with elevated expression of c-Met and beta-catenin predicts distant metastasis of colon cancer. *Clin Cancer Res* 19(3): 710–720.

Skinner AC, Steiner MJ, Henderson FW, Perrin EM (2010) Multiple markers of inflammation and weight status: cross-sectional analyses throughout childhood. *Pediatrics* 125(4): e801–e809.

Van Hemelrijck M, Jungner I, Wallidius G, Garmo H, Binda E, Hayday A, Larrieu D, Holmgren L, Hammar N (2011) Risk of prostate cancer is not associated with levels of C-reactive protein and other commonly used markers of inflammation. *Int J Cancer* 129(6): 1485–1492.

W栏idius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E (2001) High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. *Lancet* 358(928): 2026–2033.

Wang S, Liu Z, Wang L, Zhang X (2009) NF-kappaB signaling pathway, inflammation and colorectal cancer. *Cell Mol Immunol* 6(5): 327–334.

Walis G, Ahsan H (2006) Reactive oxygen species: role in the development of cancer and various chronic conditions. *J Carcinog* 5(1): 14.

Wilkins J, Gallimore JR, Moore EG, Pepys MB (1998) Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. *Clin Chem* 44(6 Part 1): 1358–1361.

Wiseman H, Halliwell B (1996) Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. *Biochem J* 313(1 Part 1): 17–29.

Wulaningsih W, Holmberg L, Garmo H, Malmstrom H, Lambe M, Hammar N, Wallidius G, Jungner I, Van Hemelrijck M (2015) Pre-diagnostic serum inflammatory markers in relation to breast cancer risk, severity at diagnosis and survival in breast cancer patients. *Carcinogenesis* 36(10): 1121–1128.

Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. *Nat Rev Cancer* 9(11): 798–809.

Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)